ALOX5 and neoplasm: A pioneering approach involves CRISPR-based ALOX5/15 gene editing, which suppresses LTB4 production and inhibits tumor growth in preclinical CAC models, offering a targeted strategy to disrupt pro-tumorigenic inflammation.